Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to $780.1 million.

  • Rhythm Pharmaceuticals' Cash & Current Investments rose 16102.35% to $780.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $780.1 million, marking a year-over-year increase of 16102.35%. This contributed to the annual value of $321.0 million for FY2024, which is 1624.16% up from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Cash & Current Investments is $780.1 million, which was up 16102.35% from $446.4 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Cash & Current Investments ranged from a high of $780.1 million in Q3 2025 and a low of $201.7 million during Q1 2024
  • Over the past 5 years, Rhythm Pharmaceuticals' median Cash & Current Investments value was $319.6 million (recorded in 2024), while the average stood at $345.9 million.
  • Per our database at Business Quant, Rhythm Pharmaceuticals' Cash & Current Investments skyrocketed by 62104.88% in 2021 and then plummeted by 4043.32% in 2022.
  • Over the past 5 years, Rhythm Pharmaceuticals' Cash & Current Investments (Quarter) stood at $295.2 million in 2021, then increased by 13.02% to $333.6 million in 2022, then decreased by 17.22% to $276.2 million in 2023, then grew by 16.24% to $321.0 million in 2024, then skyrocketed by 142.99% to $780.1 million in 2025.
  • Its last three reported values are $780.1 million in Q3 2025, $446.4 million for Q2 2025, and $522.9 million during Q1 2025.